Results 51 to 60 of about 8,428 (249)
Canadian Journal of Gastroenterology, 1990 The efficacy and tolerance of 500 mg 5-aminosalicylic acid (mesalamine) suppositories in the treatment of ulcerative proctitis were assessed in two double-blind, placebo controlled studies of six weeks' duration, involving a total of 173 patients.
CN Williams
doaj +1 more source
Ancient Science of Life, 2016 Background: Incidences of side effects and relapses are very common in chronic ulcerative colitis patients after termination of the treatment. Aims and Objectives: This study aims to compare the treatment with monoherbal formulation of Holarrhena ...
Sarika Johari, Tejal Gandhi
doaj +1 more source
One of the 5-aminosalicylates drug, mesalamine as a drug repurposing lead against breast cancer
Bulletin of the National Research Centre, 2022 Background Breast cancer is the world's second leading cause of death in women. The problem of chemoresistance in breast cancer is proving to be a challenge for researchers and several oncologists all around the world.
Dayanand Swami +4 more
doaj +1 more source
, 2009 5-aminosalicylate (5-ASA) agents remain the mainstay treatment in ulcerative colitis (UC). A number of oral 5-ASA agents are commercially available, including azobond pro-drugs, as well as delayed- and controlled-release forms of mesalazine.
Lakatos, Péter László
core +1 more source
JPGN Reports, EarlyView.Abstract Infantile‐onset inflammatory bowel disease (IOIBD) is a rare and severe subset of very‐early‐onset IBD, often associated with immune dysregulation and poor response to conventional therapies. Data regarding the use of Janus kinase inhibitors (JAKI) in this population is limited.
Smridhi Mahajan +2 more
wiley +1 more source
BMC Gastroenterology, 2013 Background Although high non-adherence to medication has been noticed for ulcerative colitis (UC), little is known about adherence to mesalamine treatments and determinants that can predict adherence.
Lachaine Jean +3 more
doaj +1 more source
Mesalamine induced side effects: clinical case presentation.
, 2023 Introduction. Mesalamine is a drug used to treat ulcerative colitis. The frequency of adverse effects of mesalamine in patients is extremely rare. Adverse effects may include gastrointestinal disorders, headache, skin reactions, arthralgia.
Zuzo, Anastasija,
core
Nutrition in Clinical Practice, EarlyView.Abstract Background The Crohn's Disease Exclusion Diet (CDED) offers a dietary means of inducing and maintaining remission for patients with Crohn's disease (CD). Descriptions of efficacy have emerged primarily from Israel, Europe, and Canada. Here, we offer real‐world experience, from a tertiary care center in the United States. Methods We conducted a
Mayah Greenfield +5 more
wiley +1 more source
Clinical Pharmacology: Advances and Applications, 2019 Abhijeet Jakate,1 Brian McNamee,2 Donald Burkindine31Clinical Pharmacology, Allergan plc, Madison, NJ, USA; 2Clinical Pharmacology, Allergan Biologics Ltd, Liverpool, UK; 3QPS Bio-Kinetic, Springfield, MO, USAObjective: Delayed-release mesalamine 400 mg ...
Jakate A, McNamee B, Burkindine D
doaj
Sustained Remission of Pediatric Bowel‐Associated Dermatosis‐Arthritis Syndrome With Risankizumab
Pediatric Dermatology, EarlyView.ABSTRACT Bowel‐associated dermatosis‐arthritis syndrome (BADAS) is a rare neutrophilic dermatosis characterized by recurrent fever, arthralgias, and skin eruptions, most commonly occurring in patients with inflammatory bowel disease. We report the case of a 17‐year‐old female with Crohn's disease who developed BADAS and achieved complete and durable ...
Kylie E. Peake +4 more
wiley +1 more source